Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
about
Self-assembling protein nanoparticles in the design of vaccinesThe S. aureus 4-oxalocrotonate tautomerase SAR1376 enhances immune responses when fused to several antigens.Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.Native-like Env trimers as a platform for HIV-1 vaccine design.HLA-DQ β1 alleles associated with Epstein-Barr virus (EBV) infectivity and EBV gp42 binding to cells.Harnessing Nanoparticles for Immunomodulation and VaccinesHIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Epstein-Barr virus: more than 50 years old and still providing surprises.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.Structure-based design of ferritin nanoparticle immunogens displaying antigenic loops of Neisseria gonorrhoeae.Characterization of the disassembly and reassembly of the HBV glycoprotein surface antigen, a pliable nanoparticle vaccine platform.A shared N-terminal hydrophobic tail for the formation of nanoparticulates.Functional interrogation and mining of natively paired human VH:VL antibody repertoires.Design of coiled-coil protein-origami cages that self-assemble in vitro and in vivo.Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.Bacterial encapsulins as orthogonal compartments for mammalian cell engineering.Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles.Structural analysis of influenza vaccine virus-like particles reveals a multicomponent organization.Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy.A new era in cytomegalovirus vaccinology: considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infectionDevelopment of a Pan-H1 Influenza Vaccine
P2860
Q26767097-C723AE75-C2C4-4258-B290-BC617B4D2D0FQ29994694-4D9C5B0C-C907-4A6E-88EC-834EEA35994DQ35994831-602E8F88-B50C-47BA-A126-A58E8F2B2179Q36627503-04CB8922-B50D-47B2-88DF-7C4DF0B83C9DQ36764365-08B7D566-5E0E-4BBC-8ED6-03C050FAD9E1Q37633417-2132B84A-906E-47FB-B553-8CD511AB762AQ37646908-1492479B-6017-43BB-A409-ABF5F5926435Q37727724-5333906E-116D-4654-ADD3-33697E9B7289Q38665463-5B043DBB-D19F-406C-A1B3-9FBF1CEF22D0Q38968588-98476BDA-8F9B-485E-86C9-0D9EA8746F6FQ39170011-46413107-8478-4B3E-BC00-E081D0E3EBEBQ40104608-0901A3D7-3F69-4CBF-AFA4-54BDCE7823E8Q40382460-D26B1E20-522A-444B-A6C1-FEEE668F08F6Q40585281-2200C40D-1CF7-4596-882E-29419A5D0EB7Q47194745-CC3B8623-3736-4DE9-9715-250E5E72CAAAQ47441562-C3E07D66-2A12-4A05-93F4-DD740EB98BACQ47547404-55FB4C24-D4B2-41AB-BEF9-186CC2FCF193Q52350559-B00AA7E7-8B0B-423E-9FD4-61C7063146B8Q54939538-2EB7B72F-D368-464A-90A0-E17C3E011701Q55189270-14EBF364-98A2-4A22-AFB1-2AB9DB76C789Q55344910-03E90896-ACE0-4227-B94B-41115E86C368Q55627667-B0F1920F-918B-4A8F-82B6-60CCBCCF878CQ55689231-1CE90D5D-0179-427F-A4D2-34AA6E94BE50Q57072187-EBB8B41E-D6F9-4FA1-8828-71761073025FQ57093727-53700252-660C-4E88-B9B1-34141FEA747B
P2860
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@ast
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@en
type
label
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@ast
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@en
prefLabel
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@ast
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@en
P2093
P2860
P50
P1433
P1476
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
@en
P2093
Adrian B McDermott
Gary J Nabel
James R R Whittle
Jeffrey I Cohen
John-Paul Todd
M Gordon Joyce
Masaru Kanekiyo
Richard A Koup
Sandeep Narpala
P2860
P304
P356
10.1016/J.CELL.2015.07.043
P407
P577
2015-08-12T00:00:00Z